证券代码：000908 证券简称：景峰医药 湖南景峰医药股份有限公司投资者关系活动记录表 | --- | --- | --- | |---------------------|----------|-----------------------------------------------------| | 投资者关系 活动类别 | ■ \n1 、 | 特定对象调研 \n国投瑞银基金管理有限公司 | | | 2 、 | 中信保诚基金管理有限公司 | | | 3 、 | 财通基金管理有限公司 | | | 4 、 | 华宝兴业基金管理有限公司 | | | 5 、 | 兴全基金管理有限公司 | | 参与单位名称 | 6 、 | 中海基金管理有限公司 | | | 7 、 | 国联安基金管理有限公司 | | | 8 、 | 兴业证券股份有限公司 | | | 9、 | 太平洋证券股份有限公司 | | | 10 、 | 平安证券股份有限公司 | | 时间 | 2018 | 年 10 月 9 日 13:00-16:00 | | 地点 | | 上海浦东新区张杨路 500 号华润时代广场 30 层 | | 上 市 公 司 接 ...

证券代码：000908 证券简称：景峰医药 编号：20190122 | --- | --- | |-----------------------|-------------------------------------------------------------| | 投资者关系 活动类别 | ■特定对象调研 | | | 1 、广发证券股份有限公司 | | | 2 、野村投资管理（上海）有限公司 | | | 3 、鹏华资产管理有限公司 | | | 4 、红土创新基金管理有限公司 | | | 5 、中天国富证券有限公司 | | | 6 、深圳菁英时代资本管理有限公司 | | | 7 、万家基金管理有限公司 | | | 8 、上海泓湖投资管理有限公司 | | | 9 、上海复杉投资管理有限公司 | | | 10 、国海证券股份有限公司 | | 参与单位名称 | 11 、中信证券股份有限公司 | | | 12 、东北证券股份有限公司 | | | 13 、中银国际证券股份有限公司 | | | 14 、平安银行股份有限公司 | | | 15 、华金证券股份有限公司 | | | 16 、德邦证券股份有限公司 | | ...

证券代码：000908 证券简称：景峰医药 编号：20190221 | --- | --- | --- | |----------------------|------------------------------------------------------------------------------------------------------------------------|----------------------------------------| | 投资者关系 活动类别 | ■特定对象调研 | | | | 1 、浙江明扬资产管理有限公司 | | | 参与单位名称 | 2 、首创证券有限责任公司 3、华林证券股份有限公司 4 、上海国际信托有限公司 5、开源证券股份有限公司 | | | | 7 、兴业证券股份有限公司 | | | | 6 、摩根士丹利华鑫证券有限责任公司 | | | | | | | 时间 2019 | 年 2 月 21 日 14:00-16:00 | | | 地点 | 上海市浦东新区张杨路 500 号 30 | 层公司会议室 | | | | | | 上市公司接待人 ...

证券代码：000908 证券简称：景峰医药 湖南景峰医药股份有限公司投资者关系活动记录表 | --- | --- | |---------------------|--------------------------------------------------------| | 投资者关系 活动类别 | ■ 特定对象调研 \n1 、 上海华信证券有限责任公司 | | | 2 、 东北证券股份有限公司 | | | 3、 平安证券股份有限公司 | | | 4 、 光大证券资产管理有限公司 | | 参与单位名称 | 5、 上海合晟资产管理股份有限公司 | | | 6 、 靖江农村商业银行 | | | 7、 中庚基金管理有限公司 | | | 8 、 富国基金管理有限公司 | | 时间 | 2019 年 2 月 20 日 14:00-16:00 | | 地点 | 上海市浦东新区张杨路 500 号 30 层 公司会议室 | | 上 市 公 司 接 待 | 毕 元 董事、董事会秘书、董事长兼总裁助理、投资部部长 | | 人员 | 张军国 人力资源总监 | | 投 资 者 关 系 活 | 问:景峰医药国际化项目进展情况？ ...

证券代码：000908 证券简称：景峰医药 湖南景峰医药股份有限公司投资者关系活动记录表 编号：20190110 | --- | --- | --- | --- | --- | |-------------------|-------------------------------------|----------------------------------------------------------|------------------------------|--------| | 投资者关系 | | ■特定对象调研 | | | | 活动类别 | 、溢联资本 | 1 | | | | | 、华林证券股份有限公司 | 2 | | | | | 、摩根士丹利华鑫证券有限责任公司 | 3 | | | | | | 4、深圳市长流资本管理有限公司 | | | | 参与单位名称 | 、富国基金管理有限公司 | 5 | | | | | 、莫尼塔（上海）信息咨询有限公司 | 6 | | | | | 、国泰基金管理有限公司 | 7 | | | | | | | | | | | | | | | | | | 8、上海利檀投资 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 402,009,285.92, representing a 28.22% increase compared to CNY 313,539,215.10 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of CNY 11,462,480.25, a decrease of 113.68% from a profit of CNY 83,787,020.29 in the previous year[21]. - The net cash flow from operating activities increased by 41.11% to CNY 59,346,453.34, compared to CNY 42,056,342.62 in the same period last year[21]. - The total assets at the end of the reporting period were CNY 1,683,030,524.52, down 6.10% from CNY 1,792,299,532.27 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 3.65% to CNY 295,212,978.94 from CNY 306,389,794.75 at the end of the previous year[21]. - The basic earnings per share were CNY -0.0130, a decline of 113.66% from CNY 0.0952 in the same period last year[21]. - The weighted average return on net assets was -3.81%, a decrease of 8.95% from 5.14% in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY -13,461,960.78, an improvement of 80.40% compared to CNY -68,675,648.08 in the previous year[21]. - The company reported a net profit of CNY 12,158,927.09, a significant decrease from CNY 85,420,457.45 in the same period of 2021, representing a decline of approximately 85.7%[180]. - The total comprehensive income for the first half of 2022 was CNY 12,719,053.44, a sharp decline from CNY 85,467,774.20 in the first half of 2021, representing a decrease of approximately 85.1%[181]. Investment and R&D - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company is committed to developing high-barrier generic drugs and has made significant progress in the anti-tumor field, with several products obtaining consistency evaluation registration certificates[42]. - The company is enhancing its research and development capabilities by establishing platforms for liposomes and nano-emulsions, focusing on high-end formulations[43]. - The company has established a multi-dimensional product pipeline, aiming for a product structure ratio of 70% chemical drugs, 20% biological drugs, and 10% traditional Chinese medicine[43]. - The company has invested 200 million CNY in R&D for new technologies, focusing on sustainable production methods[90]. - The company plans to continue its focus on research and development to enhance its product offerings and market competitiveness in the upcoming periods[197]. Market and Sales Strategy - The company’s main business remains unchanged, focusing on pharmaceutical investments, biopharmaceutical technology R&D, and medical trade[31]. - The sales approach combines direct management with academic marketing, enhancing brand image and expanding market reach[34]. - The company is exploring new media and e-commerce for market expansion, aiming to penetrate deeper into third-party and OTC markets[34]. - The company achieved a revenue of 402.01 million yuan in the first half of 2022, representing a year-on-year growth of 28.22% due to the recovery in sales of its flagship product, Xin Nao Ning capsules[48]. - The pharmaceutical segment contributed ¥395,862,440.80, accounting for 98.47% of total revenue, with a growth of 53.56% from ¥257,796,475.82[56]. Environmental Compliance - Shanghai Jingfeng reported that all monitored pollutants are within the discharge standards, including pH value at 7.9, ammonia nitrogen at 1.34 mg/L, and chemical oxygen demand at 15.4 mg/L[87]. - The total nitrogen discharge was recorded at 4.86 mg/L, which is below the regulatory limit of 60 mg/L, indicating compliance with environmental standards[87]. - The company has achieved a compliance rate of 100% for all monitored pollutants, reflecting its commitment to environmental protection[87]. - The company has implemented stringent monitoring practices to ensure all emissions remain within regulatory limits[87]. - The company has established emergency response plans for environmental incidents and has reported them to higher environmental protection authorities[103]. Risk Management - The company faces various risks, including macroeconomic and market risks, which may impact its business operations[4]. - The company faces significant risks from national policy changes affecting the pharmaceutical industry, including price negotiations and procurement policies[73]. - The company is committed to closely monitoring policy changes and adapting to national pharmaceutical reforms to maintain sustainable development[73]. - The company will strengthen market monitoring and strategic reserves of bulk materials to mitigate the risk of raw material price fluctuations[74]. Corporate Governance - The company has not sold any major assets or equity during the reporting period[70][71]. - The company has maintained a good integrity status, with no overdue debts or unfulfilled court judgments[120]. - The company has not reported any significant impact on its financial indicators due to the share changes[144]. - The company has communicated the risks associated with the uncertainty of share transfer agreements due to ongoing disputes[137]. Future Outlook - The company is exploring acquisition opportunities to strengthen its market presence and product offerings[88]. - Future outlook includes potential market expansion strategies to enhance competitive positioning[88]. - The company plans to accelerate transformation and upgrade by enhancing R&D capabilities and speeding up new product launches[74].

Revenue and Profit - The company's revenue for Q1 2022 was CNY 181,402,884.35, representing a 50.08% increase compared to CNY 120,869,292.97 in the same period last year[4] - Net profit attributable to shareholders decreased by 87.88% to CNY 3,338,005.22 from CNY 27,546,229.31 year-on-year[4] - Net profit for Q1 2022 was CNY 12,166,960.10, down 36.6% from CNY 19,202,159.72 in Q1 2021[22] - The net profit attributable to the parent company was CNY 3,338,005.22, a decline of 87.9% compared to CNY 27,546,229.31 in the previous year[22] - The company reported a basic and diluted earnings per share of CNY 0.0038, down from CNY 0.0313 in the same quarter last year[23] Cash Flow - The net cash flow from operating activities dropped significantly by 97.18% to CNY 3,446,754.01, down from CNY 122,196,127.27 in the previous year[11] - Operating cash flow net amount was CNY 3,446,754.01, significantly lower than CNY 122,196,127.27 in Q1 2021[25] - The cash flow from investing activities increased by 14.09% to CNY 84,691,218.51, attributed to the disposal of equity in Jingze Bio[11] - The net cash flow from investment activities was 84,691,218.51 CNY, an increase from 74,233,389.56 CNY in the previous year[27] - The total cash inflow from financing activities was 152,867,000.00 CNY, while the cash outflow was 105,385,861.43 CNY, resulting in a net cash flow of -105,385,861.43 CNY[27] - The cash flow from the repayment of debts was 82,401,917.78 CNY, compared to 287,201,097.23 CNY in the previous year[27] Assets and Liabilities - The company's total assets decreased by 5.80% to CNY 1,688,403,554.35 compared to CNY 1,792,299,532.27 at the end of the previous year[5] - Total assets amounted to CNY 1,688,403,554.35, a decrease from CNY 1,792,299,532.27 in the previous period[20] - Current assets totaled CNY 653,190,562.90, down from CNY 677,509,437.99 at the beginning of the year, indicating a decrease of about 3.6%[17] - Non-current assets decreased from CNY 1,114,790,094.28 to CNY 1,035,212,991.45, representing a decline of approximately 7.1%[18] - Total liabilities were CNY 1,348,506,079.20, down from CNY 1,464,569,017.32, showing a reduction of about 7.9%[19] - The company's cash and cash equivalents decreased from CNY 172,176,813.40 to CNY 154,334,239.10, a decline of approximately 10.4%[17] - Accounts receivable slightly decreased from CNY 202,233,546.35 to CNY 200,082,506.86, a reduction of about 1.1%[17] - Inventory increased from CNY 155,396,312.61 to CNY 169,620,122.84, reflecting an increase of approximately 9.1%[17] - The company's short-term borrowings decreased from CNY 475,667,122.10 to CNY 422,903,579.38, a decline of about 11.1%[18] - The total equity remained stable at CNY 339,897,475.15, unchanged from the previous period[19] - The company reported a significant reduction in other payables from CNY 238,875,678.46 to CNY 205,702,671.21, a decrease of approximately 13.9%[19] Expenses - Research and development expenses were reduced by 43.90% to CNY 4,875,944.05 from CNY 8,692,269.11 year-on-year[10] - Research and development expenses decreased to CNY 4,875,944.05 from CNY 8,692,269.11, a reduction of 43.5%[20] - Sales expenses increased to CNY 85,251,973.55 from CNY 57,471,972.67, an increase of 48.4%[20] - The company reported a 101.07% increase in non-operating expenses, totaling CNY 6,898,999.53, primarily due to fixed asset disposals and inventory write-offs[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 85,930[12] - Other comprehensive income attributable to the parent company was CNY 3,337,358.11, compared to CNY 6,543,839.44 in the previous year[23]

Financial Performance - The company's operating revenue for 2021 was CNY 811,183,491.16, representing a decrease of 7.60% compared to 2020[19]. - The net profit attributable to shareholders was a loss of CNY 163,660,189.9, an improvement of 84.68% from the previous year's loss[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 477,230,162.4, a decrease of 62.91% compared to 2020[19]. - The net cash flow from operating activities was CNY 123,834,599.70, an increase of 145.58% compared to the previous year[19]. - The company's basic and diluted earnings per share for 2021 were both -0.186 yuan, showing an improvement of 84.63% compared to -1.21 yuan in 2020[20]. - The weighted average return on equity was -39.18% in 2021, an improvement from -101.39% in 2020, indicating a 62.21% increase[20]. - Total assets decreased by 33.37% to 1,792,299,532 yuan at the end of 2021, down from 2,690,276,316 yuan at the end of 2020[20]. - The company reported a total of 313,569,972.48 yuan in non-recurring gains and losses for 2021, up from 218,023,739.61 yuan in 2020[27]. - The company achieved a total revenue of 811.18 million yuan in 2021, a decrease of 7.60% compared to the previous year[49]. - The pharmaceutical segment generated 628.89 million yuan, accounting for 77.53% of total revenue, reflecting a decline of 14.95% year-on-year[51]. Operational Challenges and Outlook - The company reported a significant internal control deficiency in financial reporting during the reporting period[5]. - The company has faced challenges in its future operations, which are discussed in the management's outlook section[5]. - The audit report issued by the accounting firm included a qualified opinion[5]. - The company is committed to ensuring the accuracy and completeness of its financial reports[4]. - The company has not changed its main business since its listing[17]. Research and Development - The company is focusing on improving the quality of generic drugs through consistency evaluations, which is expected to enhance market competitiveness in the long term[31]. - The R&D model integrates self-research and collaborative development, with a focus on key areas and leveraging partnerships with global pharmaceutical companies for innovation[36]. - The company aims to focus on progressive innovations with clinical value, targeting major diseases and planning for patent expirations to strive for first-to-file generics[37]. - The company is actively developing new products and expanding its product pipeline, with several products already in clinical trials or having received clinical approval[39]. - The company is focusing on pediatric medications, addressing the limited availability of such products in the market, with specific formulations for common childhood ailments[41]. Marketing and Sales Strategy - The sales strategy combines self-operated and outsourced models, focusing on academic marketing and expanding the sales team to enhance market presence and efficiency[35]. - The company has established a comprehensive marketing network covering all 31 provinces, cities, and autonomous regions in China, enhancing its sales in both public and private hospitals[44]. - The company plans to enhance its marketing channels and expand its sales network to achieve sales targets for its heart and brain capsules[45]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, with various pollutants being monitored and reported[157]. - All monitored pollutants, including pH, ammonia nitrogen, and chemical oxygen demand, have been reported to be within the discharge standards[157]. - The company has successfully maintained compliance with all environmental discharge standards, including total phosphorus and total nitrogen[157]. - The company has implemented measures to ensure that volatile organic compounds and particulate matter emissions are within acceptable limits[158]. - The company has a wastewater treatment capacity of 400 tons per day, operational since 2019, ensuring compliance with environmental standards[168]. Corporate Governance - The company maintained an independent business operation and governance structure, ensuring no interference from the controlling shareholder[106]. - The company has established a robust internal control system and governance structure, complying with relevant laws and regulations[109]. - The company has effectively communicated with investors through various channels, enhancing investor understanding and recognition[108]. - The company has a stable management team that adheres to established procedures for personnel appointments[108]. - The company has implemented measures to ensure fair and timely information disclosure, avoiding selective disclosure practices[108]. Financial Management and Investments - The company has adjusted its financial statements for 2020, recognizing an investment income of CNY 107,466,546.76 from the disposal of Haimen Huiju[191]. - The company acquired a 51% stake in Yibin Zhonglian Pharmaceutical Co., Ltd. for CNY 201,000 on January 28, 2021, and disposed of a 60% stake in Yunnan Liandong Co., Ltd. for CNY 32,920,000 on December 15, 2021[193]. - The company has retained the same accounting firm, Lixin Certified Public Accountants, for 8 years, with an audit fee of CNY 1,100,000 for the current period[194]. Employee Management - The total number of employees at the end of the reporting period was 846, with 49 in the parent company and 797 in major subsidiaries[135]. - The employee composition includes 405 production personnel, 222 technical personnel, and 13 sales personnel[135]. - The company has implemented a training plan aimed at enhancing professional capabilities and aligning with international standards in the generic drug industry[138]. - The company’s remuneration policy is designed to attract and retain core talent, focusing on value creation and distribution[136]. Risk Management - The company faces significant risks from policy changes in the pharmaceutical industry, which could impact production costs and profitability due to reforms in drug pricing and procurement[93]. - Fluctuations in raw material prices pose a risk to production costs, prompting the company to implement strategic reserves and develop key raw materials independently[94]. - The company is focused on mitigating R&D risks by establishing robust project management and incentive systems to ensure timely product development[99]. - Management risks associated with company expansion are being addressed by enhancing internal control systems and operational efficiency[100].

湖南景峰医药股份有限公司 2021 年第三季度报告 证券代码：000908 证券简称：景峰医药 公告编号：2021-091 湖南景峰医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 246,227,086.57 | -33.75% | 559,766,301.67 | -40.2 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 313,539,215.10, a decrease of 44.49% compared to CNY 564,828,675.97 in the same period last year[20]. - The net profit attributable to shareholders was CNY 83,787,020.29, down 39.53% from CNY 138,553,429.36 year-on-year[20]. - The basic earnings per share decreased by 39.56% to CNY 0.0952 from CNY 0.1575 in the same period last year[20]. - The operating profit for the same period was 93.81 million yuan, down 41.98% year-on-year, while the net profit attributable to shareholders was 83.79 million yuan, a decline of 39.53%[35]. - The total profit for the first half of 2021 was CNY 85,148,299.06, down from CNY 158,144,264.64 in the first half of 2020, representing a decline of 46.1%[147]. - The total comprehensive income for the first half of 2021 was CNY 85,467,774.20, compared to CNY 132,303,592.32 in the first half of 2020, a decrease of 35.4%[148]. - The company's revenue from the pharmaceutical sector was approximately ¥257.80 million, a decrease of 17.20% year-over-year, with a gross margin of 76.15%, which is an increase of 25.93% compared to the previous year[48]. Cash Flow and Investments - The net cash flow from operating activities increased by 216.93%, reaching CNY 42,056,342.62, compared to a negative cash flow of CNY -35,967,711.91 in the previous year[20]. - The company reported a significant increase in cash flow from operating activities, amounting to ¥42.06 million, compared to a negative cash flow of ¥35.97 million in the previous period[44]. - The total cash inflow from investment activities reached ¥152,181,080.00, while cash outflow was ¥11,269,951.02, resulting in a net cash flow of ¥140,911,128.98 from investment activities[154]. - The company reported a significant increase in cash received from the disposal of subsidiaries, amounting to ¥140,800,000.00 in the first half of 2021[158]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,513,364,634.40, a decrease of 6.57% from CNY 2,690,014,013.86 at the end of the previous year[20]. - The company's total liabilities as of June 30, 2021, amounted to CNY 1,811,659,943.03, a decrease of 11.7% from CNY 2,051,835,713.87 at the end of 2020[140]. - The company's cash and cash equivalents decreased to CNY 105.30 million, representing 4.19% of total assets, down from 7.10% at the end of the previous year[52]. - The company's short-term borrowings were ¥794.92 million, which is 31.63% of total assets, a decrease from 23.69% the previous year[52]. Research and Development - The company has established a product structure target aiming for a ratio of 70% chemical drugs, 20% biological drugs, and 10% traditional Chinese medicine[36]. - The company is focusing on high-barrier generic drugs and has developed a diverse R&D pipeline, including high-end formulations and innovative drug research[36]. - The company's R&D investment decreased by 78.78% to ¥22.12 million from ¥104.24 million, reflecting a strategic reduction in funding[44]. - The company has a clear R&D strategy with a rich pipeline, including products in cardiovascular, oncology, and pain management fields, with several products in various stages of approval[40]. Market and Sales Strategy - The company operates in the pharmaceutical manufacturing industry, with a focus on cardiovascular, oncology, orthopedic, women's and children's health, digestive system, anti-infection products, and medical devices[27]. - The sales strategy combines self-operated and outsourced models, focusing on academic marketing and expanding into third-party and OTC markets[31]. - The company is focusing on marketing to tiered hospitals while expanding into private hospitals and lower-tier medical markets, anticipating stable sales growth[39]. - The company achieved a hospital coverage of over 1,000 for its anti-tumor drugs, with total hospital coverage exceeding 10,000, and expects to double this number in the next five years[40]. Risk Management - The company has faced various risks, including macroeconomic and market risks, which may impact its business operations[5]. - The company is facing significant risks from policy changes in the pharmaceutical industry, which could impact production costs and profitability due to reforms in drug pricing and procurement[59]. - The fluctuation in raw material prices poses a risk to production costs, prompting the company to strengthen market monitoring and strategic reserves[61]. - The company is focused on mitigating R&D risks by implementing a structured project management approach and enhancing its organizational framework[64]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[74]. - The company achieved a COD discharge of 20 mg/L, well below the standard of ≤500 mg/L, indicating compliance[74]. - The company reported a pH level of 7.58 for wastewater discharge, within the acceptable range of 6-9[74]. - The company has maintained normal operations for all pollution control facilities across its subsidiaries[76]. Corporate Governance - The company has appointed new independent directors and a financial director as of January 26, 2021[69]. - The company did not engage in any related party transactions during the reporting period[91]. - The company has not experienced any bankruptcy restructuring matters[88]. - The half-year financial report has not been audited[86]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 100,908[117]. - The largest shareholder, Ye Xiangwu, holds 15.01% of the shares, totaling 132,075,772 shares, with a decrease of 29,054,210 shares during the reporting period[118]. - The company did not implement any share buyback during the reporting period[113]. - The total number of shares held by directors and senior management is 133,241,710 shares after accounting for changes[120].